Alto Neuroscience Inc. 2026年季度报告

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesNo The number of shares of registrant’s Common Stock outstanding as of May8, 2026 was 35,093,940. Table of Contents Part I - Financial Information Item 1. Financial Statements (Unaudited)F-1Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations20 Part II - Other Information Item 1. Legal Proceedings37Item 1A. Risk Factors37Item 2. Unregistered Sales of Equity Securities and Use of Proceeds37Item 3. Defaults Upon Senior Securities37Item 4. Mine Safety Disclosures37Item 5. Other Information38Item 6. Exhibits39Signatures40 Unless context otherwise requires, the terms the “Company,” “Alto,” “we,” “us,” “our,” and similar references in this QuarterlyReport on Form 10-Q refer to Alto Neuroscience, Inc. and its consolidated subsidiary. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements about us and our industry that involvesubstantial risks and uncertainties. All statements other than statements of historical fact contained in this Quarterly Report, includingstatements regarding our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans, orintentions relating to product candidates and markets and business trends are forward-looking statements. We have based theseforward-looking statements largely on our current expectations and projections. In some cases, you can identify forward-looking These statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performanceor achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: •the initiation, timing, progress, and results of our research and development programs, preclinical studies, any clinicaltrials, and investigational new drug, or IND, and other regulatory submissions; •the ability of our approach to reproducibly predict treatment outcomes for product candidates amongst identified patientpopulations and achieve clinical success; •our ability to continue to identify appropriate biomarkers for use in further clinical development; •the timing of and costs involved in obtaining and maintaining regulatory approval of our current product candidates andany future product candidates that we may identify or develop; •the beneficial characteristics, including potential safety, efficacy, and therapeutic effects, of our product candidates; •our ability to efficiently and cost-effectively conduct our current and future clinical trials; •our ability to obtain funding for our operations necessary to complete further development and commercialization of ourproduct candidates, if approved; •our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements, includingour ability to comply with our financial obligations pursuant to the terms of such agreements; •the timing and likelihood of the achievement of milestones pursuant to our existing collaboration and licensingagreements; •our ability to identify and develop product candidates for treatment of additional indications; •the performance of our third-party service providers, including our suppliers and manufacturers; •the rate and degree of market acceptance and clinical utility for our current product candidates and any other productcandidates we may develop; •the effects of competition with respect to our current product candidates or any of our future product candidates, as wellas innovations by current and future competitors in our industry; •our estimates regarding the potential market opportunities and the number of patients for our product candidates and anyfuture product candidates, if approved for commercial use; •the implementation of our strategic plans for our business, any product candidates we may develop; •our intellectual property position, including the scope of protection we are able to establish, maintain, defend and enforcefor intellectual property rights covering our product candidates and our Precision Psychiatry Platform; •our ability to attract and retain key scientific or management personnel; •regulatory and legal developments in the United States and foreign countries;•our ability to attract and retain employees and collaborators with development, regulatory, and commercializationexpertise;•our ability to comply with the terms of our loan agreements and our expectations reg